Cwm LLC Has $525,000 Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

CWM LLC increased its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 268.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,479 shares of the company's stock after acquiring an additional 17,112 shares during the quarter. CWM LLC's holdings in Progyny were worth $525,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in Progyny by 95.7% in the 4th quarter. Barclays PLC now owns 1,382,205 shares of the company's stock worth $23,843,000 after acquiring an additional 676,048 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in shares of Progyny in the fourth quarter worth $11,265,000. BNP Paribas Financial Markets bought a new position in shares of Progyny in the fourth quarter worth about $10,557,000. First Sabrepoint Capital Management LP purchased a new stake in Progyny during the fourth quarter valued at approximately $9,660,000. Finally, Voloridge Investment Management LLC grew its stake in shares of Progyny by 85.5% during the fourth quarter. Voloridge Investment Management LLC now owns 1,197,993 shares of the company's stock valued at $20,665,000 after buying an additional 552,066 shares during the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PGNY has been the subject of several recent analyst reports. Canaccord Genuity Group cut their price target on Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, May 12th. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a research note on Monday, March 31st. Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective for the company in a research note on Tuesday, July 8th. Leerink Partnrs raised Progyny from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 8th. Finally, Truist Financial raised their price target on Progyny from $24.00 to $27.00 and gave the stock a "hold" rating in a report on Thursday, July 17th. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Progyny presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.82.

Insider Activity

In related news, Director Cheryl Scott sold 2,675 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total value of $59,037.25. Following the sale, the director directly owned 14,112 shares of the company's stock, valued at approximately $311,451.84. This represents a 15.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.40% of the company's stock.

Progyny Trading Up 0.5%

PGNY stock traded up $0.11 on Friday, hitting $23.11. The company had a trading volume of 891,727 shares, compared to its average volume of 1,452,772. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of 40.54, a P/E/G ratio of 2.35 and a beta of 1.31. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $29.65. The stock's 50-day simple moving average is $21.91 and its 200 day simple moving average is $21.92.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a net margin of 4.33% and a return on equity of 10.90%. The business had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. During the same quarter in the prior year, the firm posted $0.17 EPS. The company's revenue for the quarter was up 16.5% compared to the same quarter last year. Research analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.